Clinical Trials Browser

Phase 2 × Enrolling by invitation × lenvatinib × Clear all

NCT05171335 2022-09-21

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

Phase 2 Enrolling by invitation

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms